A regulatory required non interventional study to monitor the safety and effectiveness of once daily treatment of orally inhaled Vahelva Respimat (Tiotropium + Olodaterol fixed dose combination 2.5µg/2.5µg per puff (2 puffs comprise one medicinal dose)) for Korean patients with COPD (Chronic Obstructive Pulmonary Disease) (Vahelva Respimat regulatory Post-marketing Surveil)